Unicycive Therapeutics (UNCY) investor relations material

Executive summary

• Focused on developing therapies for kidney disease, with main candidates oxylanthanum carbonate (OLC) for hyperphosphatemia in CKD patients and UNI-494 for acute kidney injury; OLC NDA resubmission is planned after successful third-party facility inspection.

• FDA issued a second Complete Response Letter (CRL) for OLC in June 2026, citing third-party manufacturing deficiencies; no clinical or safety concerns were raised.

• Commercial readiness initiatives for OLC are ongoing, including patient access, reimbursement support, and engagement at key industry events.

• The company continues to incur significant operating losses and expects increased expenses as it advances clinical programs and prepares for commercialization.

Financial highlights

• Net loss for the six months ended June 30, 2026 was $14.5 million, compared to $5.9 million for the same period in 2025, a 147% increase.

• Cash, cash equivalents, and marketable securities totaled $61.4 million as of June 30, 2026, providing runway into 2027.

• Total operating expenses rose 24% year-over-year to $18.6 million, driven by higher R&D and G&A costs.

• Net cash provided by financing activities was $34.0 million in the first half of 2026, mainly from sales of common stock.

• Other income was $8.4 million for Q2 2026, primarily due to an increase in the fair value of warrant liability.

Outlook and guidance

• Management expects continued operating losses and increased R&D and G&A expenses as clinical and regulatory activities progress.

• Plans to resubmit NDA for OLC following successful FDA inspection of the third-party manufacturing facility.

• Current cash is expected to fund operations for more than 12 months from the report date, supporting operations into 2027.

• Additional capital will be required to complete clinical trials and pursue commercialization.